EXTON, Pa.--(BUSINESS WIRE)--Melior Pharmaceuticals, Inc. announced today that, based upon results of its Phase 2 clinical study with Bukwang, a significant milestone has been achieved. As a result the partners will advance the compound into an additional Phase 2 clinical study. This event also triggers a success milestone to Melior. The 4-week protocol enrolled 130 diabetic subjects across 19 clinical sites in the U.S. and Korea. Based on the safety and efficacy exhibited by MLR-1023, the part
![]()
↧